News

Dermatology PAs unpack 4 frightening skin care myths and trends, from sunscreen misinformation and citrus DIYs to overusing actives and beef tallow.

Mark Lebwohl, MD, discusses patient preferences and clinical features favoring oral therapy over biologics in patients with moderate to severe plaque psoriasis.

The approval expands the IL-23 inhibitor’s indications beyond moderate-to-severe plaque psoriasis to include adults with active psoriatic arthritis.

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of October.

Clinician FAQ on remibrutinib's FDA approval in symptomatic dermographism: RemIND efficacy, mechanism, safety, and supporting CSU evidence.

Eingun James Song, MD, discusses growth considerations and height percentile outcomes with dupilumab in children with severe atopic dermatitis.

Elevate-Derm Summer 2026 faculty share practical lessons on hair loss exams, PIH, geriatric dermatology, and managing cholesterol rises on JAK inhibitors.

At Horizons in Advanced Practice, Evangelia Nezis, NP, shares early results with oral peptides and takeaways on type 2 inflammation and burnout.

Mark Lebwohl, MD, discusses atopic march data and systemic treatment options for pediatric atopic dermatitis.

A melanoma expert discusses gaps in dermoscopy education, cognitive bias during skin examinations, and strategies to improve early melanoma detection.

At Horizons in Advanced Practice, Sharon Doering, PA-C, shares how journal case reports led to rapid results for a patient with an uncommon skin condition.

Atopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.

Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.

At Horizons in Advanced Practice, Louis Margulis, PA-C, says many Medicare patients who fail topicals still can’t afford advanced therapy.

Experts outline how to recognize undertreated psoriasis, assess incomplete response, and make individualized decisions when escalating therapy.

ATI-052 improved disease severity and itch in a phase 1b trial of patients with severe atopic dermatitis, with no grade 3 or 4 adverse events.

Feldman challenges common eczema myths and highlights the disease’s effects on sleep, mental health, treatment adherence, and quality of life.

LRM will evaluate injectable rhPDGF-BB as a regenerative approach to infraorbital hollowing in a randomized phase 2b trial.

ORKA-001 achieved PASI 100 in 61% of high-dose patients at week 16 in the phase 2b EVERLAST-B trial of moderate-to-severe psoriasis.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Stratman discusses individualized eczema care, expanding treatment options, and the potential of precision medicine to guide therapy.

At the 2026 Horizons in Advanced Practice meeting, Omar Noor, MD, discussed viewing atopic dermatitis patients as type 2 inflammatory patients, growth curve data, and recent hidradenitis suppurativa guidelines.

Face taping promises smoother skin and fewer wrinkles without injectables, but evidence suggests any visible benefits are largely temporary.

Explore trending plant oils in skincare and haircare, plus 2026’s hottest actives like ectoin and hypochlorous acid—balancing glow, barrier repair, and irritation risks.

Houston dermatology clinicians compared severity scoring, JAK inhibitor safety data, and psychosocial counseling strategies across 3 alopecia areata patient cases.

Menopause can bring dryness, sensitivity, acne, and loss of firmness, requiring dermatologists to adapt skin care to patients’ changing needs.

Preview the trial data dermatology NPs and PAs will dissect in small-group sessions on AD, psoriasis, and type 2 disease at Horizons in Advanced Practice.

The September issue highlights advances in alopecia areata, cosmetic SPF, psoriasis treatment, teledermatology, and atopic dermatitis.

Phase 3 data show intismeran plus pembrolizumab reduced recurrence or death risk by 42% in patients with resected stage IIB-IV melanoma.

The 3rd annual meeting in Atlanta gives dermatology NPs and PAs 4 case-based breakout sessions and a general education session in a focused, small-group setting.